Free Access
Issue
Med Sci (Paris)
Volume 29, Number 11, Novembre 2013
Page(s) 985 - 990
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20132911014
Published online 20 November 2013
  1. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010 ; 327 : 291–295. [CrossRef] [PubMed] [Google Scholar]
  2. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011 ; 480 : 480–489. [CrossRef] [PubMed] [Google Scholar]
  3. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007 ; 13 : 552–559. [CrossRef] [PubMed] [Google Scholar]
  4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010 ; 140 : 883–899. [CrossRef] [PubMed] [Google Scholar]
  5. Chalmin F, Mignot G, Ghiringhelli F. Cellules myéloïdes suppressives et cancer : une nouvelle cible thérapeutique. Med Sci (Paris) 2010 ; 26 : 576–579. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Finn OJ. Cancer immunology. N Engl J Med 2008 ; 358 : 2704–2715. [CrossRef] [PubMed] [Google Scholar]
  7. Guha M. Anticancer TLR agonists on the ropes. Nat Rev Drug Discov 2012 ; 11 : 503–505. [CrossRef] [PubMed] [Google Scholar]
  8. Galluzzi L, Vacchelli E, Eggermont A, et al. Trial watch : experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012 ; 1 : 699–716. [CrossRef] [PubMed] [Google Scholar]
  9. Heldwein KA, Liang MD, Andresen TK, et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J Leukoc Biol 2003 ; 74 : 277–286. [CrossRef] [PubMed] [Google Scholar]
  10. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008 ; 222 : 357–368. [CrossRef] [PubMed] [Google Scholar]
  11. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012 ; 13 : 343–351. [CrossRef] [PubMed] [Google Scholar]
  12. Hu B, Elinav E, Huber S, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci USA 2010 ; 107 : 21635–21640. [CrossRef] [Google Scholar]
  13. Normand S, Delanoye-Crespin A, Bressenot A, et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci USA 2011 ; 108 : 9601–9606. [CrossRef] [Google Scholar]
  14. Allen IC, TeKippe EM, Woodford RM, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010 ; 207 : 1045–1056. [CrossRef] [PubMed] [Google Scholar]
  15. Goutagny N, Estornes Y, Hasan U, et al. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 2012 ; 7 : 29–54. [CrossRef] [PubMed] [Google Scholar]
  16. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011 ; 470 : 543–547. [CrossRef] [PubMed] [Google Scholar]
  17. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007 ; 7 : 179–190. [CrossRef] [PubMed] [Google Scholar]
  18. Rathinam VA, Vanaja SK, Waggoner L, et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell 2012 ; 150 : 606–619. [CrossRef] [PubMed] [Google Scholar]
  19. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007 ; 13 : 1050–1059. [CrossRef] [PubMed] [Google Scholar]
  20. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009 ; 15 : 1170–1178. [CrossRef] [PubMed] [Google Scholar]
  21. Bruchard M, Mignot G, Derangere V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013 ; 19 : 57–64. [CrossRef] [PubMed] [Google Scholar]
  22. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007 ; 449 : 419–426. [CrossRef] [PubMed] [Google Scholar]
  23. Zhang X, Majlessi L, Deriaud E, et al. Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity 2009 ; 31 : 761–771. [CrossRef] [PubMed] [Google Scholar]
  24. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006 ; 440 : 808–812. [CrossRef] [PubMed] [Google Scholar]
  25. Schulz O, Diebold SS, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005 ; 433 : 887–892. [CrossRef] [PubMed] [Google Scholar]
  26. Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 2010 ; 10 : 785–794. [CrossRef] [PubMed] [Google Scholar]
  27. Skoberne M, Yewdall A, Bahjat K, et al. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. J Clin Invest 2008 ; 118 : 3990–4001. [CrossRef] [PubMed] [Google Scholar]
  28. Smith KD, Andersen-Nissen E, Hayashi F, et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003 ; 4 : 1247–1253. [CrossRef] [PubMed] [Google Scholar]
  29. Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 2011 ; 477 : 592–595. [CrossRef] [PubMed] [Google Scholar]
  30. Garaude J, Kent A, van Rooijen N, Blander JM. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 2012 ; 4 : 120ra116. [CrossRef] [Google Scholar]
  31. Jamilloux Y, Henry T. Les inflammasomes : plates-formes de l’immunité innée. Med Sci (Paris) 2013 ; 29 : 975–984. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  32. Tartour E, Sandoval F, Bennefoy JY, Fridman WH. Immunothérapie des cancers. Med Sci (Paris) 2011 ; 27 : 833–841. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  33. Jobin C. Microbiome : un nouveau facteur de risque de cancer colorectal ? Med Sci (Paris) 2013 ; 29 : 582–585. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  34. Apetoh L, Ghiringhelli F, Zitvogel. La calréticuline détermine l’immunogénicité de la chimiothérapie et de la radiothérapie anti-tumorales. Med Sci (Paris) 2007 ; 23 : 257–258. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.